Lantheus Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Lantheus Holdings wird ein Gewinn- und Umsatzwachstum von 11% bzw. 13% pro Jahr prognostiziert, während der Gewinn pro Aktie um 8.7% pro Jahr wachsen soll.

Wichtige Informationen

11.0%

Wachstumsrate der Gewinne

8.7%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	13.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus

May 23

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

May 10

Lantheus Holdings: Powerful First Quarter

May 05

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

Apr 12

Lantheus Holdings: Undervalued With A Good Outlook

Feb 28

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Feb 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

May 29

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Apr 16

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Feb 27

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Jan 16

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Dec 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Oct 31

Does This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?

Oct 04

Looking In On Lantheus Holdings

Sep 14

Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent

Aug 25

Lantheus Non-GAAP EPS of $0.89 beats by $0.19, revenue of $223.72M beats by $19.21M

Aug 04

Lantheus Holdings (NASDAQ:LNTH) May Have Issues Allocating Its Capital

Jul 22

Lantheus Holdings Rules The Medical Diagnostics Business World

Jul 06

We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease

Jun 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:LNTH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,815	586	642	654	8
12/31/2025	1,571	439	684	341	10
12/31/2024	1,502	437	777	542	11
3/31/2024	1,366	461	268	324	N/A
12/31/2023	1,296	327	213	305	N/A
9/30/2023	1,206	104	-46	298	N/A
6/30/2023	1,125	33	-61	275	N/A
3/31/2023	1,027	-18	60	380	N/A
12/31/2022	935	28	3	282	N/A
9/30/2022	801	107	172	190	N/A
6/30/2022	664	32	87	101	N/A
3/31/2022	542	-37	42	54	N/A
12/31/2021	425	-71	42	54	N/A
9/30/2021	390	-34	29	41	N/A
6/30/2021	376	-27	32	45	N/A
3/31/2021	341	-8	5	17	N/A
12/31/2020	339	-13	4	16	N/A
9/30/2020	335	0	25	38	N/A
6/30/2020	332	12	43	56	N/A
3/31/2020	352	25	65	79	N/A
12/31/2019	347	32	58	80	N/A
9/30/2019	344	35	51	75	N/A
6/30/2019	347	39	47	73	N/A
3/31/2019	347	42	44	72	N/A
12/31/2018	343	41	41	61	N/A
9/30/2018	338	124	38	57	N/A
6/30/2018	329	124	31	48	N/A
3/31/2018	333	127	34	49	N/A
12/31/2017	331	123	N/A	55	N/A
9/30/2017	324	31	N/A	54	N/A
6/30/2017	318	27	N/A	54	N/A
3/31/2017	307	21	N/A	51	N/A
12/31/2016	302	27	N/A	50	N/A
9/30/2016	299	26	N/A	49	N/A
6/30/2016	300	27	N/A	39	N/A
3/31/2016	295	-5	N/A	10	N/A
12/31/2015	293	-15	N/A	22	N/A
9/30/2015	299	-18	N/A	5	N/A
6/30/2015	301	-25	N/A	20	N/A
3/31/2015	303	-2	N/A	27	N/A
12/31/2014	302	-4	N/A	12	N/A
9/30/2014	296	-16	N/A	12	N/A
6/30/2014	291	-30	N/A	-5	N/A
3/31/2014	286	-43	N/A	-15	N/A
12/31/2013	284	-62	N/A	-16	N/A
9/30/2013	284	-59	N/A	-34	N/A
6/30/2013	288	-72	N/A	-37	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LNTHDas prognostizierte Gewinnwachstum (11% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: LNTHDie Erträge des Unternehmens (11% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: LNTHDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: LNTHDie Einnahmen des Unternehmens (13% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.5% pro Jahr).

Hohe Wachstumseinnahmen: LNTHDie Einnahmen des Unternehmens (13% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LNTH in 3 Jahren voraussichtlich hoch sein wird

Lantheus Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 27%

Price target increased by 8.3% to US$106

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Price target decreased by 7.7% to US$108

Recent updates

Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Consensus EPS estimates increase by 27%

Lantheus Holdings: Powerful First Quarter

Price target increased by 8.3% to US$106

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

CFO & Treasurer notifies of intention to sell stock

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Chairman of the Board notifies of intention to sell stock

Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients

Investor sentiment improves as stock rises 15%

Lantheus Holdings: Undervalued With A Good Outlook

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Full year 2023 earnings: EPS exceeds analyst expectations

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate)

Now 25% undervalued after recent price drop

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Market Participants Recognise Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Earnings

Investor sentiment deteriorates as stock falls 22%

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Price target decreased by 7.7% to US$108

Now 31% undervalued after recent price drop

CFO & Treasurer notifies of intention to sell stock

Return Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Appealing

A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

CEO & Director notifies of intention to sell stock

Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?

New major risk - Earnings quality

New major risk - Revenue and earnings growth

Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Returns At Lantheus Holdings (NASDAQ:LNTH) Appear To Be Weighed Down

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

CEO & Director notifies of intention to sell stock

Calculating The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New minor risk - Earnings quality

Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?

Ratio Therapeutics Inc. In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for Pet Imaging

Insufficient new directors

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Chief Administrative Officer notifies of intention to sell stock

Price target increased by 7.4% to US$120

Lantheus Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Business Officer notifies of intention to sell stock

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

CEO & Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021)

Investor sentiment improves as stock rises 17%

Lantheus Holdings, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Lantheus Holdings, Inc. Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Lantheus Holdings, Inc. (NasdaqGM:LNTH) acquired Cerveau Technologies, Inc.

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

Senior VP notifies of intention to sell stock